CompletedNot Applicable

Eplerenone, Aflibercept and Topical Nepafenac Serous Foveal Deta Chment in Central Serous Chorioretinopathy

Egypt16 participantsStarted 2023-02-28

Plain-language summary

describing the influence of; combined Eplerenone, intravitreal Aflibercept, and topical Nepafenac; on serous foveal detachment in eyes with CSCR

Who can participate

Age range16 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * CSCR eyes treated by combination of Eplerenone, Aflibercept and Nepafenac. Exclusion Criteria: * • CSCR treated by other modalities * CSCR treated by just 1 or 2 components of :Eplerenone, Aflibercept and Nepafenac

What they're measuring

Change in central macular thickness (CMT ) in microns

Timeframe: (baseline, 6 months)

Change in serous detachment height (SDH) in microns

Timeframe: (baseline, 6 months)

Trial details

NCT IDNCT05847049

SponsorDar El Oyoun Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-03-25

View on ClinicalTrials.gov More Central Serous Chorioretinopathy trials